

# Add the p40 Antibody to Your Menu

Agilent-developed rabbit monoclonal antibody DAK-p40 in FLEX RTU format for Dako Omnis



## IHC staining for p40 supports tumor classification in non-small cell lung cancer

The classification of non-small cell lung cancer into adenocarcinoma and squamous cell carcinoma is important for treatment decisions<sup>1</sup>. Studies have shown that antibodies against the  $\Delta$ Np63 isoform (p40) of the p63 protein show better specificity in distinguishing squamous cell carcinoma from adenocarcinoma compared to antibodies that detect the full length p63 protein<sup>1</sup>.

The Dako Omnis p40 FLEX RTU antibody is based on a new Agilent-developed rabbit monoclonal DAK-p40 clone and validated for use in lung squamous cell carcinoma classification<sup>2</sup>.


- New Agilent-developed rabbit monoclonal antibody
- FLEX RTU quality and ease-of-use
- Validated for use in classification of lung squamous cell carcinoma

Agilent  
**Dako**


### p63 Antibodies

In addition to the new p40 antibody, we offer an antibody clone DAK-p63, that detects both the TAp63 and  $\Delta$ Np63 isoforms of the p63 protein.


**IHC staining with FLEX RTU anti-p40, clone DAK-p40 on low-expressor tissue (placenta), high-expressor tissue (tonsil) and clinical tissue (lung squamous cell carcinoma and lung adenocarcinoma)**




**Figure 1.** Placenta, weak to moderate nuclear staining in the cytotrophoblasts.



**Figure 2.** Tonsil, strong nuclear staining in squamous epithelium and no staining in lymphocytes.



**Figure 3.** Lung squamous cell carcinoma, strong nuclear staining of neoplastic cells.



**Figure 4.** Lung adenocarcinoma, no staining of neoplastic cells.

## Incorporate p40 RTU into your Dako Omnis workflow

The standardized FLEX RTU concept and the Dako Omnis workflow capabilities work together to enable your lab to run the required tests for your patients efficiently, minimizing hands-on time related to sorting and re-assembly of cases, and accelerating time to diagnosis<sup>3</sup>.



### Workflow benefits

The FLEX RTU concept provides a simple, efficient workflow:

- Fully calibrated antibodies that ensure easy and straightforward implementation
- Appropriate plug-and-play protocols to ensure that the antigen is correctly demonstrated in both high and low tissue expression structures
- Precise control recommendations support monitoring of staining results and efficient QC

This supports your lab goal of achieving reliable and reproducible diagnostic results.

## Integrated quality control

Dako Omnis is designed with a host of integrated quality control features to ensure accurate staining results:

- A double check of reagent vials helps avoid dispensing problems and ensures that the necessary volumes are dispensed onto the slides
- The Dynamic Gap Staining process provides full and even reagent coverage of the slide to deliver consistent staining slide after slide
- A temperature-controlled reagent environment maintains reagent integrity, and a stable temperature (32 °C) throughout the staining process
- Full traceability of patient cases

## References

1. Yatabe Y, et al. Best practices recommendations for diagnostic immunohistochemistry in lung cancer; J Thorac Oncol, 2019;14(3):377-407.
2. Package insert for FLEX Ready-to-Use Monoclonal Rabbit Anti-Human p40, Clone DAK-40, Code GA784 . Available at <https://www.agilent.com/library/eifu>. Last accessed 30 July, 2021.
3. Agilent Case Study: Dako Omnis Workflow. Lab Achieves 74% Increase in Same-Day Patient Case Completion. Available at [https://www.agilent.com/cs/library/casestudies/public/29295\\_case\\_study\\_dako\\_omnis\\_dutch\\_experience.pdf](https://www.agilent.com/cs/library/casestudies/public/29295_case_study_dako_omnis_dutch_experience.pdf). Last accessed 30 July, 2021.

**Table 2.** Ordering details

Target	Product	Package Size	Part No.
p40	FLEX Monoclonal Rabbit Anti-Human p40, Clone DAK-p40, Ready-to-Use (Dako Omnis)	12 mL, 60 tests	GA78461-2

D67548

This information is subject to change without notice.

© Agilent Technologies, Inc. 2021  
Published in the USA, September 1, 2021  
29444 2021AUG25